Effect of the dipeptidyl peptidase-4 inhibitor linagliptin on structural manifestations of diabetic nephropathy was studied in BKS.Cg-Dock7m+/+Leprdb/J mice (experimental model of type 2 diabetes mellitus). Linagliptin (10 mg/kg per day) or vehicle was administered by gavage over 8 weeks. Mesangial expansion, thickening of the basement membrane in glomerular capillaries and proximal tubules, and retraction of cytopodia were less pronounced in mice receiving linagliptin. The protective effect of linagliptin on the kidney structure was not associated with its hypoglycemic action.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Ametov AS, Karpova EV. Clinical application of DPP-4 inhibitor vildaglipinin in type 2 diabetes mellitus. Russ. Med. Zh. 2010:18(14):887-891. Russian.
Bondar IA, Klimontov VV, Nadeyev AP, Bgatova NP. Early renal changes in type 1 diabetes. Probl. Endokrinol. 2007:53(5):3-8. Russian.
Betz B, Conway BR. Recent advances in animal models of diabetic nephropathy. Nephron Exp. Nephrol. 2014:126(4):191-195.
Haluzik M, Frolik J, Rychlik I. Renal Effects of DPP-4 Inhibitors: A focus on microalbuminuria. Int. J. Endocrinol. 2013:2013. doi: 10.1155/2013/895102.
Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors–from preclinical development to clinical research. Kidney Blood Press. Res. 2012:36(1):65-84.
Holderied A, Romoli S, Eberhard J, Konrad LA, Devarapu SK, Marschner JA, Muller S, Anders HJ. Glomerular parietal epithelial cell activation induces collagen secretion and thickening of Bowman’s capsule in diabetes. Lab. Invest. 2015:95(3):273-282.
Hyvonen ME, Dumont V, Tienari J, Lehtonen E, Ustinov J, Havana M, Jalanko H, Otonkoski T, Miettinen PJ, Lehtonen S. Early-onset diabetic E1-DN mice develop albuminuria and glomerular injury typical of diabetic nephropathy. Biomed. Res. Int. 2015:2015. doi: 10.1155/2015/102969.
Ioannidis I. Diabetes treatment in patients with renal disease: Is the landscape clear enough? World J. Diabetes. 2014:5(5):651-658.
Jung E, Kim J, Ho Kim S, Kim S, Cho MH. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy. Eur. J. Pharmacol. 2015:761:116-124.
Sharkovska Y, Reichetzeder C, Alter M, Tsuprykov O, Bachmann S, Secher T, Klein T, Hocher B. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J. Hypertens. 2014:32(11. P. 2211-2223.
Teng B, Duong M, Tossidou I, Yu X, Schiffer M. Role of protein kinase C in podocytes and development of glomerular damage in diabetic nephropathy. Front. Endocrinol. (Lausanne). 2014:5:179. doi: 10.3389/fendo.2014.00179.
Vavrinec P, Henning RH, Landheer SW, Wang Y, Deelman LE, Dokkum RP, Buikema H. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat. Curr. Vasc. Pharmacol. 2014:12(6. P. 836-844.
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 161, No. 4, pp. 489-493, April, 2016
Rights and permissions
About this article
Cite this article
Gavrilova, Y.S., Bgatova, N.P., Klimontov, V.V. et al. Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus. Bull Exp Biol Med 161, 501–504 (2016). https://doi.org/10.1007/s10517-016-3447-6
- type 2 diabetes mellitus
- diabetic nephropathy